December 7, 2024 - 13:50
Microchip Technology has decided to pause its pursuit of federal funding under the CHIPS Act, which was initially intended to support the expansion of its Gresham facility. The company was slated to receive a substantial $162 million from the 2022 CHIPS Act, with $72 million earmarked specifically for the Gresham expansion project.
This decision comes amid changing market conditions and shifting company priorities. The Gresham facility has been a critical part of Microchip's operations, contributing to its overall production capabilities. However, the company is now reassessing its strategy in light of recent developments in the semiconductor industry and broader economic factors.
The CHIPS Act was designed to bolster domestic semiconductor manufacturing, but Microchip's pause raises questions about the future of similar projects across the industry. Stakeholders will be closely monitoring how this decision impacts the company's growth trajectory and its commitment to investing in U.S. manufacturing infrastructure.
July 1, 2025 - 12:35
Westville Library Receives Grant for Technology and Internet EnhancementsWESTVILLE — In an era where technology is rapidly transforming our daily lives, the Westville Public Library in Vermilion County is taking significant steps to modernize its services. The library...
June 30, 2025 - 22:18
Webstar Technology Group Secures Contract for "The Forge" Project in Downtown AtlantaWebstar Technology Group, a prominent player in real estate development and digital asset innovation, has officially placed its transformative project, `The Forge,` under contract in the heart of...
June 30, 2025 - 04:30
Voice-Based Risk Assessment Firm Secures $60 Million in Series D FundingClearspeed, a prominent player in the voice-based risk assessment technology sector, has successfully raised $60 million in its Series D funding round. This latest investment elevates the company`s...
June 29, 2025 - 04:10
First Patient Enrolled in Groundbreaking Study on MicroPulse Technology for DMEA significant milestone has been reached in a clinical study evaluating the effectiveness of MicroPulse technology as an adjunct to anti-VEGF therapy for patients suffering from diabetic macular...